Usana Health Sciences (USNA) Fundamental Analysis: Revenue, Earnings & Valuation

8.35 / 10

Outperform

Fundamentally, USNA rates Outperform with an 8.3/10 score. Asset‑MV and Profit‑MV are strong, while Cash‑MV and Revenue‑MV lag. ROA, profit margins and EBIT ratios are robust, delivering overall excellent financial health.

Analysis Checks(8/10)

Revenue-MV

Value0.96

Score1/3

Weight-6.09%

1M Return-0.97%

ROA (%)

Value1.54

Score3/3

Weight13.17%

1M Return1.81%

Net cash flow from operating activities / Operating revenue (%)

Value2.42

Score2/3

Weight10.48%

1M Return1.48%

Profit-MV

Value-0.03

Score2/3

Weight22.62%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value1.54

Score3/3

Weight13.17%

1M Return1.81%

EBIT / Total operating revenue (%)

Value4.32

Score3/3

Weight11.26%

1M Return1.53%

Asset-MV

Value-0.49

Score3/3

Weight34.35%

1M Return4.62%

Net profit / Total operating revenue (%)

Value1.24

Score3/3

Weight10.07%

1M Return1.41%

Cash-MV

Value-0.09

Score1/3

Weight-21.44%

1M Return-4.16%

Net profit / Total profit (%)

Value27.64

Score3/3

Weight12.42%

1M Return1.76%

Is USNA undervalued or overvalued?

USNA scores 8.35/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 1.24% net margin, 30.01 P/E ratio, 0.55 P/B ratio, and 0.00% earnings growth, these metrics solidify its Outperform investment rating.